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Background/aim: Gemcitabine (GEM) has antiproliferative effects on lymphocytes, which are potent pathogenic actors of rheumatoid
arthritis (RA). The aim of the study was to investigate the therapeutic potential of GEM on collagen-induced arthritis (CIA).
Materials and methods: Arthritis was induced by the intradermal injection of chicken type II collagen with incomplete Freund’s
adjuvant into albino Wistar rats. Doses of 5 and 20 mg/kg GEM were administered twice a week after the 14th day, which marked the
onset the arthritis. Serum IL-17, TNF-α, malondialdehyde, catalase, superoxide dismutase (SOD), and glutathione peroxidase (GPx)
levels and tissue heme oxygenase-1 (HO-1) and nuclear factor erythroid 2-related factor 2 (Nrf2) levels were analyzed.
Results: Histopathologically prevalent inflammation and cartilage/bone destruction were observed in the arthritis group. Moreover, in
the arthritis group serum IL-17, TNF-α, and malondialdehyde levels were significantly increased while catalase, SOD, GPx, HO-1, and
Nrf2 levels were significantly decreased. However, in the GEM-treated groups, decreased TNF-α, IL-17, and malondialdehyde levels;
increased SOD, catalase, GPx, Nrf2, and HO-1 levels; and ameliorated perisynovial inflammation and cartilage/bone destruction were
observed.
Conclusion: GEM suppresses cytokine levels and enhances antioxidant activity. It also prevents cartilage/bone destruction in the CIA
model. GEM may be a viable candidate for research into the treatment of RA.
Key words: Rheumatoid arthritis, collagen-induced arthritis, gemcitabine, western blotting

1. Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory
illness characterized by persistent immune activation
(1). B and T cells play crucial roles in the pathogenesis
of RA (2,3). There are several mechanisms that trigger
immune activation in RA. Leukocyte migration, mediated
by chemokines and chemokine receptors, is recognized
to have a crucial role in the progression of inflammation
in rheumatoid synovium (4). Leukocytes including T
cells infiltrate the synovium and produce cytokines such
as tumor necrosis factor-α (TNF-α), interleukin (IL)1β, IL-6, and IL-17. T cell-mediated immune response
is considered a critical contributor in the initiation and
progression of RA pathogenesis. On the other hand, B
cells produce autoantibodies such as rheumatoid factor
and anticyclic citrullinated peptide antibody (2,5,6).
* Correspondence: kocassk@yahoo.com

Oxidative stress is associated with the pathogenesis of
RA (7,8). Free radicals such as superoxide and hydrogen
peroxide are released from inflammatory cells in the
synovial fluid of RA patients. They cause joint damage and
pannus formation (7,8). However, antioxidant enzymes
play a role in the defense system against free radicals.
Nuclear factor erythroid 2-related factor 2 (Nrf2), a
cytoprotective transcriptional factor for the upregulation
of the antioxidant response element (ARE) pathway,
enhances the expression of several antioxidants (9).
Gemcitabine (GEM) is a nucleoside antimetabolite.
It is an analog of deoxycytidine, which blocks
deoxyribonucleic acid synthesis. GEM is converted to
active metabolites including difluorodeoxycytidinediphosphate and -triphosphate after being transported
into the cell. The triphosphate analog replaces one of the
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nucleic acid building blocks during DNA replication.
Moreover, GEM inhibits the ribonucleotide reductase
enzyme. Therefore, it is used to treat several malignant
tumors (e.g., ovarian and breast cancers) (10). In addition,
GEM possesses antiproliferative and apoptotic effects on T
and B lymphocytes (11).
The purpose of the present study is to evaluate the
potential therapeutic efficacy of GEM in an in vivo
experimental model of RA, collagen-induced arthritis
(CIA).
2. Materials and methods
2.1. Animals
The study was started after approval was obtained from
the Ethics Committee of Fırat University. The experiment
was conducted with 40 female albino Wistar rats of 10
weeks old weighing from 200 to 250 g. The rats were kept
in separate cages at a humidity of 55 ± 5% and 22 ± 2 °C
for a 12-h photophase and a 12-h scotophase. Standard rat
feed was used for their nutrition, and they were given ad
libitum access to water.
2.2. Experimental design
The study was conducted by dividing the rats into four
groups: control, arthritis (placebo), low-dose GEM, and
high-dose GEM. Each group consisted of 10 subjects. The
first group was the control group. Arthritis was induced
via collagen injection in the other three groups. Type 2
collagen, obtained from Sigma-Aldrich (St. Louis, MO,
USA), was diluted with 0.1 M acetic acid to reach 1 mg
in 1 mL. The collagen solution was emulsified with an
equal amount of incomplete Freund’s adjuvant (Difco
Laboratories, Detroit, MI, USA). The prepared solution
was injected intradermally into the dorsal tail (100 µg)
and back paws (50 µg to each paw and a total of 200
µg to each rat) on the first day. A volume of prepared
solution of 100 µg was applied to the dorsal tail for booster
injections 7 days later. Development of arthritis after the
collagen injection was individually evaluated for each rat
by clinical scoring. Arthritis scorings for the study groups
were done according to a previously described method
(12). According to the clinical scoring, prominent arthritis
was observed on the 12th and 13th days in the collageninjected groups (Figure 1); hence, GEM treatment was
started on the 14th day.
GEM dosages of 5 and 20 mg/kg were given
intraperitoneally to the 3rd and 4th groups, respectively,
twice a week after the 14th day, which was the beginning
of arthritis. The GEM dosages were determined according
to a previous study (13). The same volume of physiological
serum was injected intraperitoneally into the control and
arthritis (placebo) groups twice per week from the 14th to
the 29th day.
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2.3. Sample acquisition
Rats were euthanized on the 29th day. Back paws were
amputated under the knee joint for further examination,
and blood samples were taken for biochemical analysis.
The blood samples were centrifuged and harvested sera
were stored at –20 °C until analysis. Joint samples were
divided into two sections for western blot (WB) analysis
and histopathological examination. The section for the
WB analysis was kept at –80 °C and did not undergo any
manipulation. The remaining section was put into 10%
formaldehyde for histopathological examination.
2.4. Laboratory analyses
Serum malondialdehyde (MDA) levels were measured by
the high-performance liquid chromatography (Shimadzu,
Tokyo, Japan). Serum superoxide dismutase (SOD),
catalase (CAT), and glutathione peroxidase (GPx) levels
were analyzed using the appropriate commercial kits
(Cayman Co., Ann Arbor, MI, USA) in accordance
with the enzyme-linked immunosorbent assay (ELISA)
method. Serum TNF-α (Invitrogen, Camarillo, CA, USA)
and IL-17 (Wuhan USCN Business Co., Ltd., Wuhan,
China) levels were measured using the ELISA method.
2.5. Western blot measurements
Joint tissue samples were analyzed for the expression
of Nrf2 and heme oxygenase-1 (HO-1), using the
WB technique. The hind paws of all rats were rapidly
excised from the euthanized rats and then immediately
frozen at –80 °C. Small pieces of the paw joints in each
group of animals were pooled together for WB analysis.
Homogenates were prepared in an ice-cold lysis buffer
containing 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 5
mM EDTA, 1% Triton X-100, 0.26% sodium deoxycholate,
50 mM sodium fluoride, 10 mM β-glycerophosphate,
0.1 mM sodium orthovanadate, 10 µg/mL leupeptin,
and 50 µg/mL phenylmethylsulfonyl fluoride and then
incubated on ice for 40 min. Next, 80 µL of 10% Nonidet
P-40 solution was added to the homogenates, and the
mixture was then centrifuged for 2 min at 14,000 × g at
4 °C to remove cellular debris and isolate total protein.
Concentration of the protein was determined according
to the procedure described by Lowry et al. (14) using a
protein assay kit supplied by Sigma-Aldrich. A sodium
dodecyl sulfate-polyacrylamide gel electrophoresis
sample buffer containing 2% β-mercaptoethanol was
added to the supernatant. Equal amounts of protein (50
µg) were electrophoresed and subsequently transferred
to nitrocellulose membranes (Schleicher and Schuell
Inc., Keene, NH, USA). Nitrocellulose blots were washed
twice for 5 min each in phosphate-buffered saline (PBS)
and blocked with 1% bovine serum albumin in PBS for
1 h prior to application of the primary antibody. The
antibodies against Nrf2 and HO-1 were purchased from
Abcam Inc. (Cambridge, UK). The primary antibody
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3. Results
3.1. Clinical scoring of arthritis
Paws were slightly erythematous after the first injections
of collagen in the arthritis (placebo) and GEM-treated
groups. From 12th to the 13th day, there was permanent

arthritis in the collagen-injected groups (arthritis and
GEM-treated groups) compared to the control group (P
< 0.05 for all). In the arthritis group, the mean arthritis
score on the 29th day was higher than the score of the
same group on the 14th day (P < 0.05). However, the mean
arthritis scores on the 29th day were lower compared to the
14th day scores in the low- and high-dose GEM-treated
groups (P < 0.001 for both). On the other hand, the mean
arthritis scores of the 29th day were significantly lower in
both GEM-treated groups compared to the arthritis group
(Table 3; Figure 1).
None of rats in the control or arthritis group died. One
rat in the low-dose GEM group and two rats in the highdose GEM group died. However, these increased mortality
rates (10% and 20%, respectively) were not statistically
significant compared to the control and arthritis groups
(P > 0.05 for both groups). On the other hand, diarrhea
was detected in two rats (22.2%) and three rats (37.5%) in
the low- and high-dose GEM-treated groups, respectively,
while diarrhea was not found in the control or the arthritis
group. Similar to the mortality rates, the increase noted
in diarrhea (dose-dependent) in the GEM-treated groups
compared to the control and arthritis groups was not
statistically significant (P > 0.05 for both groups).
3.2. Histopathological scoring
According to the scoring results, a significant decrease
was found in inflammation and destruction in both
GEM-treated groups (P < 0.001) (Table 3). However, the
destruction score in the group with the high dose of GEM
had more significant improvement (P < 0.05), while the
improvements of the inflammation score were similar in
both of the GEM-treated groups (P > 0.05) (Table 3; Figure
2).
3.3. Serum cytokine levels
Serum TNF-α and IL-17 concentrations were found to be
higher in the placebo group than in the control group (P
< 0.01 for both). However, their levels were lower in the
GEM-treated groups than in the placebo group (P < 0.01
for all). In the GEM-treated groups, serum TNF-α levels
were similar in the control group (P > 0.05), while serum

Table 1. Histopathological assessment of inflammation severity.

Table 2. Histopathological assessment of arthritis severity.

was diluted (1:1000) in the same buffer containing 0.05%
Tween-20. The nitrocellulose membrane was incubated
overnight at 4 °C with protein antibody. The blots were
washed and incubated with horseradish peroxidaseconjugated goat antimouse IgG (Abcam). Specific
binding was detected using diaminobenzidine and H2O2
as substrates. Protein loading was controlled using a
monoclonal mouse antibody against β-actin antibody
(A5316; Sigma-Aldrich). Blots were performed at least
three times to confirm the reproducibility of the results.
Bands were analyzed densitometrically using an image
analysis program (Image J; National Institutes of Health,
Bethesda, MD, USA).
2.6. Histopathological evaluations
Tissue samples fixed in formalin solution were decalcified
with 10% nitric acid (30 days) to prepare paraffin blocks.
Cross-sections taken from the blocks were stained with
hematoxylin and eosin (H&E). They were then examined
by a specialist pathologist under 40×, 100×, 200×, and
400× magnifications with a light microscope to assess
inflammatory cell infiltration, pannus formation, and bone
destruction around the joint. The samples were scored on a
scale between 0 and 4 points for histopathological scoring
(Tables 1 and 2) as previously described (15,16).
2.7. Statistical analysis
Data were analyzed using IBM SPSS 21.0 (IBM Corp.,
Armonk, NY, USA). Data were expressed as mean ±
standard deviation. Data were analyzed with Kruskal–
Wallis variance analysis. The Mann–Whitney U test was
used for dual comparisons. Categorical data were analyzed
by the chi-square test. The differences in the arthritis
scoring from the 14th to the 29th day were evaluated with
the Wilcoxon rank-sum test. All P-values of less than 0.05
were accepted as statistically significant.

Perisynovial tissue (PT) inflammation severity

Score

Arthritis severity

Score

Normal PT

0

Normal cartilage and bone tissue

0

PT inflammation, no aggregates

1

Synovial hyperplasia or hypertrophy

1

PT inflammation, occasional small focal aggregates

2

Pannus or superficial cartilage erosion

2

Moderate PT inflammation, many small aggregates

3

Subchondral erosion, mild bone erosion

3

Diffuse PT inflammation and large aggregates

4

Marked bone erosion

4
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Table 3. Clinical and laboratory data in the study groups.
n = 10 for each group

Control

Arthritis

GEM, 5 mg/kg

GEM, 20 mg/kg

14th day arthritis score

-

1.4 ± 0.7

1.4 ± 0.5

1.7 ± 0.4

29th day arthritis score

-

2.4 ± 0.5

e

0.4 ± 0.2

0.2 ± 0.3e

Inflammation score

-

4.0 ± 0.0

1.8 ± 0.6e

1.3 ± 0.6e

Cartilage/bone destruction score

-

3.9 ± 0.3

1.1 ± 0.6e

0.5 ± 0.5e,f

TNF-α (pg/mL)

25.6 ± 5.0

62.7 ± 12.9b

25.8 ± 4.9d

30.8 ± 5.5d

IL-17 (pg/mL)

29.5 ± 8.3

65.7 ± 8.9b

47.4 ± 4.6b,d

44.7 ± 5.6 b, d

MDA (µmol/L)

0.58 ± 0.23

1.6 ± 0.2b

0.91 ± 0.28a,d

0.76 ± 0.32d

SOD (U/mL)

12.0 ± 7.3

3.4 ± 1.6b

4.9 ± 1.3b,c

4.8 ± 1.4b

CAT (nmol min–1 mL–1)

0.33 ± 0.07

0.12 ± 0.08b

0.26 ± 0.05d

0.30 ± 0.07e

GPx (nmol min–1 mL–1)

335.5 ± 179.2

179.1 ± 45.2b

362.1 ± 208.4c

351.7 ± 243.4c

Data are presented as mean ± standard deviation.
GEM: Gemcitabine, TNF: tumor necrosis factor, IL: interleukin, MDA: malondialdehyde, SOD: superoxide dismutase, CAT: catalase,
GPx: glutathione peroxidase. When compared to the control group: aP < 0.05, bP < 0.01. When compared to the arthritis group: cP <
0.05, dP < 0.01, eP < 0.001. When compared to the GEM (5 mg/kg) group: fP < 0.05.

Figure 1. Assessments of daily arthritis score in all study groups.
×
P < 0.05 in the arthritis and GEM-treated groups compared to the
control group.
*P < 0.001 in the GEM-treated groups compared to the arthritis group.

IL-17 levels were still higher than in the control group (P
< 0.01 for both) (Table 3). Serum TNF-α and IL-17 levels
were similar in both the GEM-treated groups.
3.4. Oxidants and antioxidants
Serum MDA levels were higher in the placebo group than
in the control group (P < 0.01). However, its level was lower
in the GEM-treated groups than in the placebo group (P
< 0.01 for both) (Table 3). No significant difference was
observed for MDA levels between the GEM-treated groups
(P > 0.05).
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SOD, CAT, and GPx levels were lower in the placebo
group than in the control group (P < 0.01 for all). However,
CAT and GPx levels were higher in the GEM-treated
groups compared to the placebo group (Table 3). SOD
levels were significantly higher in the low-dose GEMtreated group, but it was relatively higher in the high-dose
GEM-treated group.
The results of WB analysis are presented in Figure 3. The
tissue Nrf2 and HO-1 levels were lower in the placebo group
when compared to the control group (P < 0.05 for both).
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Figure 2. Histopathological sections of joints in the study groups (H&E, 400×). Synovial and perisynovial tissue was normal
in the control group (A). Perisynovial inflammation and destruction of cartilage/bone were obvious in the placebo group (B).
Perisynovial inflammation and synovial hyperplasia were ameliorated in the GEM-treated groups with low (C) and high (D) doses.

Figure 3. Western blot analysis and densitometric quantifications of Nrf2 (A) and HO-1 (B). Representative blots, repeated at least 3
times (n = 4), are shown. Actin was included to ensure equal protein loading. The densitometric quantifications were normalized to
actin densities for each sample and expressed as mean ± SD.
*The tissue Nrf2 and HO-1 levels were lower in the arthritis (placebo) group compared to the control group (P < 0.05). ‡On the other
hand, they were higher in the GEM-treated groups compared to the arthritis group (P < 0.05). Nrf2: Nuclear factor erythroid 2-related
factor 2, HO-1: heme oxygenase-1, GEM: gemcitabine, GEM-5: low-dose gemcitabine group, GEM-20: high-dose gemcitabine group.
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Both GEM-treated groups had increased Nrf2 and HO-1
levels compared to the placebo group (P < 0.05 for all).
4. Discussion
RA primarily affects small- and medium-sized joints
(17,18). Systemic involvements such as the respiratory,
cardiovascular, and hematopoietic systems may also
occur. The typical lesion is synovitis, leading to the chronic
inflammation of the synovial membrane and formation of
pannus, which ultimately leads to joint destruction (4). In
RA, joint destruction causes deformities and reduces the
quality of life in patients. Thus, these patients experience
a high rate of work-related disabilities. Moreover, the
treatment of RA patients puts a heavy economic burden
on many countries, and today’s basic goal is to minimize
or fully remove this burden. Although great improvements
have occurred in current RA treatment modalities,
side effects and the ineffectiveness of treatment remain
limitations of the current medications. Therefore, new
therapeutic agents are required in the treatment of RA.
Gemcitabine is a pyrimidine antimetabolite that is
anabolized to a difluorodeoxycytidine-triphosphate,
which is incorporated into DNA and is used to treat
several cancers. Nowak et al. (11) showed that GEM causes
a profound depletion of lymphocytes and impairs antigenspecific cellular and humoral immunity. Conversely, it
has been reported that GEM therapy decreases the count
of memory T cells but does not deplete the activation of
inflammatory cells (19). GEM treatment has resulted
in the upregulation of IL-23R in the A549 cell line (20).
On the other hand, Landi et al. (21) reported that GEM
attenuated psoriasis, an inflammatory disease. In our
study, GEM ameliorated arthritis in a CIA model.
T cells are widely known to orchestrate the inflammatory
process in RA, even though the pathogenesis of RA has
not yet been fully elucidated (2,3). Th17 cells and IL-17
are two important agents in RA pathogenesis (22). It was
reported that IL-17 provoked inflammations through
other proinflammatory cytokines, including TNF-α and
IL-1, and it leads to massive cartilage and bone destruction
(23–25). Another study reported that IL-17 antibody
treatment prevented cartilage and bone destruction (26).
In our study, GEM applications decreased IL-17 levels.
TNF-α is a cytokine with a significant function in RA
pathogenesis, and it was previously reported that it exists in
high amounts in synovial liquids and tissues. In addition,
the serum level of soluble TNF receptors has been shown
to be associated with increased inflammation and activity
of the disease in RA patients (27,28). Currently, anti-TNF
agents are used widely and successfully to treat RA. In our
study, the mean TNF-α level was decreased in the GEMtreated groups in addition to the IL-17 level. According to
these results, it can be concluded that the antiarthritic effect
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of GEM is a consequence of its antiinflammatory effects.
Previous studies have demonstrated the antiinflammatory
potential of GEM in in vitro settings (11,19).
Oxidative stress increases in patients with RA (7).
The radical derivatives of oxygen, such as superoxide and
hydrogen peroxide, are the most important free radicals.
Reactive oxygen radicals are released from inflammatory
cells in the synovium and they contribute to pannus
formation and joint damage (8). SOD, CAT, and GPx
are antioxidant enzymes that play prominent roles in the
defense system against reactive oxygen species. Increased
free radical products can cause decreased antioxidant
enzyme levels. Previous studies have reported decreased
activity of antioxidant enzymes in patients with RA
(29–31). In another study, Iyama et al. (32) showed that
SOD treatment reduces cartilage/bone destruction and
proinflammatory cytokines in experimentally induced
arthritis. In our study, we determined that SOD, CAT, and
GPx levels were increased in the GEM-treated groups.
Malondialdehyde, one of the reactive aldehydes, is a
product of lipid peroxidation and it plays a role in oxidative
stress. Reactive aldehydes cause damage in the membrane
structure and other cell components (28). Previous studies
found an increase in MDA levels in the synovial liquids
and serums of RA patients (33,34). Our study documented
that the MDA level was increased in the arthritis group
compared to the control group, and it was decreased in the
GEM-treated group compared to the arthritis group.
Nrf2, a redox-sensitive transcription factor, binds to
ARE. ARE enhances genes encoding many detoxifying or
antioxidant enzymes. Moreover, Nrf2 is related to stressresponsive proteins including glutathione S-transferase,
GPx, and HO-1. Thus, Nrf2 regulates the redox status
and plays a key role in cellular defense by enhancing the
removal of reactive oxygen species (35). It was documented
that Nrf2 knockout mice had more severe cartilage injuries
and more oxidative damage in an experimental arthritis
group (36). It was also reported that the expressions of
Nrf2 target genes are enhanced in Nrf2 wild-type mice,
but not in knockout mice (36,37). These results support
a protective role of Nrf2 against joint inflammation. In
our study, Nrf2 and HO-1 expressions were decreased in
the arthritis group, while GEM treatment increased their
expressions. Duong et al. (38) documented that in vitro
GEM applications increased the expressions of Nrf2 and
HO-1. GEM can activate Nrf2 and HO-1. These positive
effects of GEM may also be a consequence of its direct
antiinflammatory effect. However, in both situations, the
antioxidant potential of GEM may ultimately contribute to
its antiarthritic effects.
The limitations of our study are as follows. First,
it documents the early effects of GEM treatments on
arthritis, but not its long-term effects, which also need to
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be researched. Second, radiographic progressions need to
be evaluated.
In conclusion, GEM, a nucleoside antimetabolite,
decreases the levels of TNF-α and IL-17, increases

antioxidant activity, and prevents cartilage/bone
destruction in the CIA model. The present study suggests
that GEM may be a viable candidate for research on the
treatment of RA.
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